What should an ideal vaccine postlicensure safety system be?
In 2007 the National Vaccine Program, along with the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health, and the Health Resources and Services Administration, sponsored a public conference titled "Vaccine Safety Evaluation: Post Marketing Surveillance." The objective was to discuss enhanced approaches to postlicensure evaluation of vaccine safety, including active and passive surveillance systems and special studies. The conference participants reviewed the evolution of the assessment of vaccine safety, detailed current national approaches to postmarketing safety, and offered new approaches to evaluating vaccine safety. A number of the participants recommended that information systems be expanded to include reliable information on vaccination and health outcomes in large populations. We summarize the major meeting presentations and discussions.
Griffin
Marie R
MR
Departments of Preventive Medicine and Medicine, School of Medicine, Vanderbilt University, Nashville, TN, USA.
Braun
M Miles
MM
Bart
Kenneth J
KJ
D016907:Adverse Drug Reaction Reporting Systems; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects*; D007251:Influenza, Human / Q000517:prevention & control*; D011159:Population Surveillance; D014481:United States
D007252:Influenza Vaccines